Debra L. Weiner, M.D., Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Anemia, Sickle Cell | 9 | 2023 | 1018 | 0.790 |
Why?
|
| Pediatrics | 7 | 2020 | 3475 | 0.510 |
Why?
|
| Disasters | 2 | 2011 | 511 | 0.440 |
Why?
|
| Benzocaine | 1 | 2011 | 15 | 0.410 |
Why?
|
| Disaster Planning | 3 | 2014 | 549 | 0.320 |
Why?
|
| Rescue Work | 1 | 2006 | 56 | 0.270 |
Why?
|
| Clinical Trials Data Monitoring Committees | 1 | 2004 | 25 | 0.250 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 2004 | 323 | 0.220 |
Why?
|
| Disaster Medicine | 1 | 2024 | 75 | 0.220 |
Why?
|
| Antisickling Agents | 1 | 2003 | 80 | 0.220 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 3133 | 0.210 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 3240 | 0.210 |
Why?
|
| Analgesia, Patient-Controlled | 2 | 2013 | 109 | 0.210 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2004 | 629 | 0.200 |
Why?
|
| Hydroxyurea | 1 | 2003 | 290 | 0.200 |
Why?
|
| Urea Cycle Disorders, Inborn | 1 | 2021 | 31 | 0.200 |
Why?
|
| Pain | 6 | 2023 | 4986 | 0.200 |
Why?
|
| Mass Casualty Incidents | 1 | 2024 | 183 | 0.190 |
Why?
|
| Computer Systems | 1 | 2003 | 483 | 0.190 |
Why?
|
| National Heart, Lung, and Blood Institute (U.S.) | 1 | 2022 | 314 | 0.190 |
Why?
|
| Terbutaline | 1 | 2000 | 24 | 0.190 |
Why?
|
| National Institute of Child Health and Human Development (U.S.) | 1 | 2020 | 26 | 0.190 |
Why?
|
| Pandemics | 1 | 2020 | 8388 | 0.180 |
Why?
|
| Emergency Medical Services | 2 | 2014 | 1917 | 0.170 |
Why?
|
| Metabolism, Inborn Errors | 1 | 2021 | 288 | 0.170 |
Why?
|
| Emergency Medicine | 3 | 2024 | 1207 | 0.170 |
Why?
|
| Adrenergic beta-Agonists | 1 | 2000 | 346 | 0.160 |
Why?
|
| Vasodilator Agents | 1 | 2003 | 977 | 0.160 |
Why?
|
| Transportation of Patients | 2 | 2011 | 185 | 0.150 |
Why?
|
| Nitric Oxide | 2 | 2004 | 2132 | 0.150 |
Why?
|
| Relief Work | 2 | 2011 | 137 | 0.150 |
Why?
|
| Invertebrate Hormones | 1 | 1996 | 26 | 0.150 |
Why?
|
| Cardiopulmonary Resuscitation | 2 | 2019 | 980 | 0.140 |
Why?
|
| Medical Records Systems, Computerized | 2 | 2013 | 1205 | 0.130 |
Why?
|
| Clinical Trials as Topic | 2 | 2020 | 7913 | 0.130 |
Why?
|
| Escherichia coli Infections | 2 | 1996 | 532 | 0.130 |
Why?
|
| Emergency Service, Hospital | 4 | 2023 | 7659 | 0.130 |
Why?
|
| Internship and Residency | 3 | 2024 | 5788 | 0.120 |
Why?
|
| Safety | 2 | 2011 | 1186 | 0.110 |
Why?
|
| Research | 2 | 2020 | 1999 | 0.110 |
Why?
|
| Hospitals, Public | 1 | 2014 | 207 | 0.110 |
Why?
|
| Vascular Diseases | 2 | 2019 | 1161 | 0.110 |
Why?
|
| Patient Selection | 2 | 2012 | 4215 | 0.100 |
Why?
|
| Hemoglobin SC Disease | 1 | 2011 | 22 | 0.100 |
Why?
|
| Blood Grouping and Crossmatching | 1 | 2012 | 107 | 0.100 |
Why?
|
| Southwestern United States | 1 | 2011 | 37 | 0.100 |
Why?
|
| Southeastern United States | 1 | 2011 | 95 | 0.100 |
Why?
|
| Child | 13 | 2024 | 77709 | 0.100 |
Why?
|
| Blood Group Incompatibility | 1 | 2012 | 146 | 0.100 |
Why?
|
| Security Measures | 1 | 2011 | 77 | 0.100 |
Why?
|
| Blood Group Antigens | 1 | 2012 | 180 | 0.090 |
Why?
|
| Educational Measurement | 2 | 2019 | 1210 | 0.090 |
Why?
|
| Serum Amyloid A Protein | 2 | 2000 | 121 | 0.090 |
Why?
|
| Analgesics, Opioid | 3 | 2023 | 3674 | 0.090 |
Why?
|
| Anti-Infective Agents | 1 | 1996 | 972 | 0.080 |
Why?
|
| Isoantibodies | 1 | 2012 | 679 | 0.080 |
Why?
|
| Erythrocyte Transfusion | 1 | 2012 | 565 | 0.070 |
Why?
|
| Apolipoproteins | 2 | 2000 | 317 | 0.070 |
Why?
|
| Heart | 1 | 2000 | 4467 | 0.070 |
Why?
|
| United States Government Agencies | 1 | 2006 | 26 | 0.070 |
Why?
|
| Louisiana | 1 | 2006 | 108 | 0.070 |
Why?
|
| United States | 7 | 2024 | 69872 | 0.070 |
Why?
|
| Troponin | 2 | 2000 | 524 | 0.060 |
Why?
|
| Sepsis | 2 | 1996 | 2593 | 0.060 |
Why?
|
| Needs Assessment | 1 | 2011 | 1147 | 0.060 |
Why?
|
| Angina, Unstable | 2 | 2000 | 926 | 0.060 |
Why?
|
| Education, Medical, Undergraduate | 1 | 2013 | 1008 | 0.060 |
Why?
|
| Data Collection | 1 | 2013 | 3341 | 0.060 |
Why?
|
| Counseling | 1 | 2011 | 1523 | 0.060 |
Why?
|
| Clinical Protocols | 1 | 2009 | 1462 | 0.050 |
Why?
|
| Point-of-Care Systems | 1 | 2011 | 1177 | 0.050 |
Why?
|
| Humans | 26 | 2024 | 744343 | 0.050 |
Why?
|
| Pilot Projects | 3 | 2008 | 8324 | 0.050 |
Why?
|
| Early Termination of Clinical Trials | 2 | 2012 | 68 | 0.050 |
Why?
|
| Leishmania infantum | 1 | 2001 | 17 | 0.050 |
Why?
|
| Infusions, Intravenous | 2 | 2011 | 2274 | 0.050 |
Why?
|
| Opsonin Proteins | 1 | 2001 | 150 | 0.050 |
Why?
|
| Clinical Competence | 3 | 2019 | 4687 | 0.050 |
Why?
|
| Asthma | 1 | 2000 | 6011 | 0.050 |
Why?
|
| Mannans | 1 | 2001 | 63 | 0.050 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2004 | 780 | 0.050 |
Why?
|
| Leishmaniasis, Visceral | 1 | 2001 | 94 | 0.050 |
Why?
|
| Fetal Hemoglobin | 1 | 2003 | 341 | 0.050 |
Why?
|
| Research Support as Topic | 1 | 2004 | 705 | 0.050 |
Why?
|
| Fentanyl | 1 | 2023 | 410 | 0.050 |
Why?
|
| Administration, Inhalation | 1 | 2003 | 1105 | 0.040 |
Why?
|
| Triage | 1 | 2006 | 976 | 0.040 |
Why?
|
| Pain Measurement | 2 | 2013 | 3420 | 0.040 |
Why?
|
| Nephelometry and Turbidimetry | 1 | 1998 | 91 | 0.040 |
Why?
|
| Lectins | 1 | 2001 | 513 | 0.040 |
Why?
|
| Curriculum | 2 | 2024 | 3605 | 0.040 |
Why?
|
| Creatine | 1 | 2000 | 421 | 0.040 |
Why?
|
| Creatine Kinase | 1 | 2000 | 694 | 0.040 |
Why?
|
| Laboratories | 1 | 2021 | 463 | 0.040 |
Why?
|
| Health Personnel | 1 | 2011 | 3218 | 0.040 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2013 | 9959 | 0.040 |
Why?
|
| Rwanda | 1 | 2019 | 703 | 0.040 |
Why?
|
| United States Food and Drug Administration | 1 | 2004 | 1584 | 0.040 |
Why?
|
| C-Reactive Protein | 2 | 1998 | 3778 | 0.040 |
Why?
|
| Carrier Proteins | 2 | 2001 | 5021 | 0.040 |
Why?
|
| Education, Medical, Graduate | 2 | 2008 | 2291 | 0.040 |
Why?
|
| Protein Precursors | 1 | 2000 | 1154 | 0.030 |
Why?
|
| Isoenzymes | 1 | 2000 | 1726 | 0.030 |
Why?
|
| Random Allocation | 2 | 1996 | 2429 | 0.030 |
Why?
|
| United Arab Emirates | 1 | 2014 | 42 | 0.030 |
Why?
|
| Adolescent | 8 | 2019 | 85781 | 0.030 |
Why?
|
| Computer Simulation | 1 | 2008 | 6196 | 0.030 |
Why?
|
| Antimicrobial Cationic Peptides | 1 | 1996 | 362 | 0.030 |
Why?
|
| Endotoxins | 1 | 1996 | 527 | 0.030 |
Why?
|
| Peritonitis | 1 | 1995 | 365 | 0.030 |
Why?
|
| Prospective Studies | 5 | 2003 | 53288 | 0.030 |
Why?
|
| Health Resources | 1 | 2019 | 911 | 0.030 |
Why?
|
| Male | 13 | 2023 | 350118 | 0.030 |
Why?
|
| Rats, Wistar | 1 | 1996 | 1901 | 0.030 |
Why?
|
| Acute Chest Syndrome | 1 | 2012 | 31 | 0.030 |
Why?
|
| Child, Preschool | 4 | 2019 | 41006 | 0.030 |
Why?
|
| Practice Guidelines as Topic | 1 | 2009 | 7279 | 0.030 |
Why?
|
| Hydromorphone | 1 | 2011 | 65 | 0.020 |
Why?
|
| Mammary Neoplasms, Experimental | 1 | 1994 | 520 | 0.020 |
Why?
|
| Female | 13 | 2023 | 380194 | 0.020 |
Why?
|
| Patient Discharge | 1 | 2023 | 3313 | 0.020 |
Why?
|
| Odds Ratio | 1 | 2021 | 9849 | 0.020 |
Why?
|
| Double-Blind Method | 1 | 2003 | 12026 | 0.020 |
Why?
|
| Adult | 9 | 2019 | 214055 | 0.020 |
Why?
|
| Tumor Necrosis Factor-alpha | 2 | 2001 | 4420 | 0.020 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 1994 | 1038 | 0.020 |
Why?
|
| Multicenter Studies as Topic | 1 | 2013 | 1677 | 0.020 |
Why?
|
| Morphine | 1 | 2011 | 657 | 0.020 |
Why?
|
| Survival Rate | 2 | 2000 | 12788 | 0.020 |
Why?
|
| Health Care Surveys | 1 | 2012 | 2453 | 0.020 |
Why?
|
| Foreign Medical Graduates | 1 | 2005 | 79 | 0.020 |
Why?
|
| Amniotic Fluid | 1 | 1985 | 370 | 0.010 |
Why?
|
| Learning | 1 | 2013 | 1713 | 0.010 |
Why?
|
| Resource Allocation | 1 | 2005 | 341 | 0.010 |
Why?
|
| Feasibility Studies | 1 | 2012 | 5078 | 0.010 |
Why?
|
| Collectins | 1 | 2001 | 18 | 0.010 |
Why?
|
| Cross-Sectional Studies | 1 | 2023 | 25043 | 0.010 |
Why?
|
| Observer Variation | 1 | 2008 | 2593 | 0.010 |
Why?
|
| Australia | 1 | 2005 | 1170 | 0.010 |
Why?
|
| Treatment Outcome | 2 | 2009 | 63114 | 0.010 |
Why?
|
| Disease Models, Animal | 2 | 1996 | 18029 | 0.010 |
Why?
|
| Rats | 1 | 1996 | 24260 | 0.010 |
Why?
|
| Canada | 1 | 2005 | 2065 | 0.010 |
Why?
|
| Amino Acids | 1 | 1985 | 1736 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2011 | 10943 | 0.010 |
Why?
|
| Sensitivity and Specificity | 2 | 2008 | 14722 | 0.010 |
Why?
|
| Mannose-Binding Lectins | 1 | 1998 | 100 | 0.010 |
Why?
|
| Immune Sera | 1 | 1998 | 641 | 0.010 |
Why?
|
| Antibodies, Monoclonal | 1 | 1995 | 9274 | 0.010 |
Why?
|
| Length of Stay | 1 | 2011 | 6309 | 0.010 |
Why?
|
| Logistic Models | 1 | 2013 | 13408 | 0.010 |
Why?
|
| Retrospective Studies | 2 | 2019 | 77449 | 0.010 |
Why?
|
| Research Design | 1 | 2013 | 5987 | 0.010 |
Why?
|
| Myocardial Infarction | 1 | 1998 | 11727 | 0.010 |
Why?
|
| Adenocarcinoma | 1 | 1994 | 6364 | 0.010 |
Why?
|
| Fellowships and Scholarships | 1 | 2005 | 1076 | 0.010 |
Why?
|
| Evaluation Studies as Topic | 1 | 1998 | 1681 | 0.010 |
Why?
|
| Young Adult | 2 | 2012 | 56430 | 0.010 |
Why?
|
| Prevalence | 1 | 2012 | 15226 | 0.010 |
Why?
|
| Middle Aged | 5 | 2012 | 213383 | 0.010 |
Why?
|
| Reference Standards | 1 | 1998 | 1025 | 0.010 |
Why?
|
| Immunoassay | 1 | 1998 | 752 | 0.010 |
Why?
|
| Age Factors | 1 | 2011 | 18370 | 0.010 |
Why?
|
| Bicarbonates | 1 | 1995 | 313 | 0.010 |
Why?
|
| Disease Susceptibility | 1 | 2001 | 1782 | 0.010 |
Why?
|
| G(M1) Ganglioside | 1 | 1994 | 96 | 0.010 |
Why?
|
| Tumor Cells, Cultured | 1 | 2001 | 6314 | 0.010 |
Why?
|
| Troponin T | 1 | 1998 | 754 | 0.010 |
Why?
|
| Mice, Inbred C3H | 1 | 1994 | 964 | 0.010 |
Why?
|
| Animals | 4 | 2001 | 168757 | 0.010 |
Why?
|
| Risk Assessment | 1 | 2014 | 23338 | 0.010 |
Why?
|
| Interleukin-6 | 1 | 2001 | 3200 | 0.010 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 1998 | 3870 | 0.010 |
Why?
|
| Thrombolytic Therapy | 1 | 2000 | 2161 | 0.010 |
Why?
|
| Cytotoxicity, Immunologic | 1 | 1994 | 1369 | 0.010 |
Why?
|
| Fibrinolytic Agents | 1 | 2000 | 2158 | 0.010 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 1995 | 1375 | 0.010 |
Why?
|
| Immunophenotyping | 1 | 1994 | 1880 | 0.010 |
Why?
|
| Rabbits | 1 | 1995 | 4894 | 0.010 |
Why?
|
| Electrocardiography | 1 | 2000 | 6442 | 0.000 |
Why?
|
| Aged | 2 | 2012 | 163280 | 0.000 |
Why?
|
| Case-Control Studies | 1 | 2001 | 21746 | 0.000 |
Why?
|
| Amino Acids, Branched-Chain | 1 | 1985 | 251 | 0.000 |
Why?
|
| Pregnancy Trimester, Second | 1 | 1985 | 732 | 0.000 |
Why?
|
| Survival Analysis | 1 | 1995 | 10252 | 0.000 |
Why?
|
| Predictive Value of Tests | 1 | 1998 | 15076 | 0.000 |
Why?
|
| Reproducibility of Results | 1 | 1998 | 19905 | 0.000 |
Why?
|
| Blood Pressure | 1 | 1995 | 8554 | 0.000 |
Why?
|
| Infant | 1 | 2001 | 35136 | 0.000 |
Why?
|
| Prognosis | 1 | 2000 | 29063 | 0.000 |
Why?
|
| Cells, Cultured | 1 | 1994 | 19229 | 0.000 |
Why?
|
| Reference Values | 1 | 1985 | 4982 | 0.000 |
Why?
|
| Aged, 80 and over | 1 | 2001 | 57776 | 0.000 |
Why?
|
| Mice | 1 | 1994 | 81183 | 0.000 |
Why?
|
| Pregnancy | 1 | 1985 | 29144 | 0.000 |
Why?
|